Status:
COMPLETED
Stellate Ganglion Block to Reduce Hot Flushes
Lead Sponsor:
Rijnstate Hospital
Conditions:
Hot Flash
Stellate Ganglion Block
Eligibility:
FEMALE
30-70 years
Phase:
NA
Brief Summary
To assess the short-term efficacy of stellate ganglion block on hot flush reduction versus sham procedure
Detailed Description
Hot flushes are the most common symptom of menopause for which postmenopausal (PMP) women seek medical help, in 20% of PMP women hot flushes can persist for up to 15 years. A possible treatment for h...
Eligibility Criteria
Inclusion
- Female
- Age: 30-70 years
- Mean daily flush frequency of 10 or more and a hot flush score of 15 or more
- Absence of any non-menopausal cause of flushing
- Post-menopause amenorrhea for more than 1 year in healthy postmenopausal women
- In case of breast cancer or ovariectomy induced menopause: ovariectomy for \> 6 months. Adjuvant therapy with estrogen-receptor blocker or an aromatase inhibitor.
Exclusion
- Use of medication that affects flushing:oestrogens, progestogens, clonidine, naloxone, paroxetine, fluoxetine, venlafaxine, gabapentin, luteïniserend hormone releasing hormones receptor antagonist
- Receiving chemotherapy of radiotherapy
- Active psychiatric disease
- Active concurrent disease
- Allergic reactions against local anesthetics of the 'amide' type or contrast media.
Key Trial Info
Start Date :
September 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2019
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT03756272
Start Date
September 1 2017
End Date
February 1 2019
Last Update
March 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rijnstate hospital
Arnhem, Netherlands